{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:18:28Z","timestamp":1794917908591,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with tuberous sclerosis complex (TSC) face an increased risk of maternal health complications and worsening disease manifestations during pregnancy. There are no established consensus guidelines that address the management of pregnancy in patients with TSC and healthcare providers rely on their individual experiences and preferences to derive treatment decisions. We sought to obtain provider opinion of pregnancy related maternal complications in patients with TSC, and the common evaluation and management strategies used to address these issues.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a cross-sectional survey of healthcare providers with diverse areas of expertise related to the multisystem nature of involvement in TSC. Descriptive analyses were used to analyze our three primary variables: (1) provider recognition of maternal risks\/complications; (2) provider recommendations before and during pregnancy; and (3) provider\/clinic protocols.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We received responses from 87 providers from 11 countries, with 40.7% (n\u2009=\u200935) seeing\u2009&gt;\u200930 TSC patients yearly. The majority of providers (n\u2009=\u200970, 88.6%) deemed that a patient with TSC needed expert care beyond the standard of care for a typical pregnancy, with over 25% of providers reporting that they have seen lymphangioleiomyomatosis (LAM) exacerbation, seizures, and preterm labor in pregnant patients with TSC. Providers who managed patients treated with mTOR inhibitors (mTORi) also agreed that mTORi use should be stopped prior to pregnancy (n\u2009=\u200945, 68.2%) but there was uncertainty about when to stop the mTORi (one month 28.9%, two months 11.1%, three months 42.2%, and 6\u201312\u00a0months 2.2%). Additionally, there were mixed opinions on restarting mTORi in response to disease progression during pregnancy. When asked about provider or clinic specific protocols, 71.6% (n\u2009=\u200953) of providers stated that they do not have a clear protocol for management decisions for patients with TSC before or during pregnancy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Healthcare providers recognize that patients with TSC are at an increased risk for maternal health complications during pregnancy. However, there are wide inter-individual variances in practice, especially pertaining to decisions regarding mTORi use. There is a critical need to better understand the implications of pregnancy for patients with TSC, and to draft consensus recommendations to guide management decisions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-03015-7","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T16:07:31Z","timestamp":1704211651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Healthcare provider recognition of pregnancy related risks and management considerations in patients with tuberous sclerosis complex"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0196-1987","authenticated-orcid":false,"given":"Meredith","family":"Rose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandra","family":"Tolusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Wakefield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"issue":"13","key":"3015_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMra055323","volume":"355","author":"PB Crino","year":"2006","unstructured":"Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345\u201356.","journal-title":"N Engl J Med"},{"issue":"1","key":"3015_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-022-02266-0","volume":"17","author":"C Luo","year":"2022","unstructured":"Luo C, Ye W-R, Shi W, Yin P, Chen C, He Y-B, et al. Perfect match: mTOR inhibitors and tuberous sclerosis complex. Orphanet J Rare Dis. 2022;17(1):1\u201316.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"3015_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/ajmg.c.31655","volume":"178","author":"DN Franz","year":"2018","unstructured":"Franz DN, Krueger DA. mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018;178(3):365\u201373.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"7","key":"3015_CR4","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3906\/sag-2002-133","volume":"50","author":"SP Uysal","year":"2020","unstructured":"Uysal SP, Sahin M. Tuberous sclerosis: a review of the pastpresent and future. Turk J Med Sci. 2020;50(7):1665\u201376.","journal-title":"Turk J Med Sci"},{"key":"3015_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","volume":"123","author":"H Northrup","year":"2021","unstructured":"Northrup H, Aronow ME, Bebin EM, Bissler J, Darling TN, De Vries PJ, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol. 2021;123:50\u201366.","journal-title":"Pediatr Neurol"},{"issue":"02","key":"3015_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1055\/s-2005-861572","volume":"22","author":"JA King","year":"2005","unstructured":"King JA, Stamilio DM. Maternal and fetal tuberous sclerosis complicating pregnancy: a case report and overview of the literature. Am J Perinatol. 2005;22(02):103\u20138.","journal-title":"Am J Perinatol"},{"issue":"3","key":"3015_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/uog.11227","volume":"41","author":"KA Lee","year":"2013","unstructured":"Lee KA, Won H-S, Shim J-Y, Lee PR, Kim A. Molecular genetic, cardiac and neurodevelopmental findings in cases of prenatally diagnosed rhabdomyoma associated with tuberous sclerosis complex. Ultrasound Obstet Gynecol. 2013;41(3):306\u201311.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"11","key":"3015_CR8","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/pd.464","volume":"22","author":"R Gamzu","year":"2002","unstructured":"Gamzu R, Achiron R, Hegesh J, Weiner E, Tepper R, Nir A, et al. Evaluating the risk of tuberous sclerosis in cases with prenatal diagnosis of cardiac rhabdomyoma. Prenat Diagn. 2002;22(11):1044\u20137.","journal-title":"Prenat Diagn"},{"issue":"2","key":"3015_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ogc.2018.01.010","volume":"45","author":"S Harris","year":"2018","unstructured":"Harris S, Vora N. Maternal genetic disorders in pregnancy. Obstet Gynecol Clin North Am. 2018;45(2):249\u201365.","journal-title":"Obstet Gynecol Clin North Am"},{"key":"3015_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pediatrneurol.2021.09.014","volume":"125","author":"D Ebrahimi-Fakhari","year":"2021","unstructured":"Ebrahimi-Fakhari D, Stires G, Hahn E, Krueger D, Franz DN. Prenatal sirolimus treatment for rhabdomyomas in tuberous sclerosis. Pediatr Neurol. 2021;125:26\u201331.","journal-title":"Pediatr Neurol"},{"issue":"12","key":"3015_CR11","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1007\/s00381-021-05218-4","volume":"37","author":"S Cavalheiro","year":"2021","unstructured":"Cavalheiro S, da Costa MDS, Richtmann R. Everolimus as a possible prenatal treatment of in utero diagnosed subependymal lesions in tuberous sclerosis complex: a case report. Childs Nerv Syst. 2021;37(12):3897\u20139.","journal-title":"Childs Nerv Syst"},{"issue":"3","key":"3015_CR12","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/pd.5613","volume":"40","author":"ID Pluym","year":"2020","unstructured":"Pluym ID, Sklansky M, Wu JY, Afshar Y, Holliman K, Devore GR, et al. Fetal cardiac rhabdomyomas treated with maternal sirolimus. Prenat Diagn. 2020;40(3):358\u201364.","journal-title":"Prenat Diagn"},{"issue":"3","key":"3015_CR13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/uog.20196","volume":"53","author":"C Vachon-Marceau","year":"2019","unstructured":"Vachon-Marceau C, Guerra V, Jaeggi E, Chau V, Ryan G, Van Mieghem T. In-utero treatment of large symptomatic rhabdomyoma with sirolimus. Ultrasound Obstet Gynecol. 2019;53(3):420\u20131.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"19","key":"3015_CR14","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1056\/NEJMc1800352","volume":"378","author":"BT Barnes","year":"2018","unstructured":"Barnes BT, Procaccini D, Crino J, Blakemore K, Sekar P, Sagaser KG, et al. Maternal sirolimus therapy for fetal cardiac rhabdomyomas. N Engl J Med. 2018;378(19):1844\u20135.","journal-title":"N Engl J Med"},{"issue":"5","key":"3015_CR15","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1080\/15513815.2021.1948646","volume":"41","author":"A Dagge","year":"2021","unstructured":"Dagge A, Silva L, Jorge S, Nogueira E, Rebelo M, Pinto L. Fetal tuberous sclerosis: sirolimus for the treatment of fetal rhabdomyoma. Fetal Pediatr Pathol. 2021;41(5):800\u20136.","journal-title":"Fetal Pediatr Pathol"},{"issue":"12","key":"3015_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3390\/jcm7120552","volume":"7","author":"C Ponticelli","year":"2018","unstructured":"Ponticelli C, Moroni G. Fetal toxicity of immunosuppressive drugs in pregnancy. J Clin Med. 2018;7(12):552.","journal-title":"J Clin Med"},{"issue":"2","key":"3015_CR17","first-page":"153","volume":"28","author":"M Faehling","year":"2011","unstructured":"Faehling M, Frohnmayer S, Leschke M, Trinajstic-Schulz B, Weber J, Liewald F. Successful pregnancy complicated by persistent pneumothorax in a patient with lymphangioleiomyomatosis (LAM) on sirolimus. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):153\u20135.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"3","key":"3015_CR18","first-page":"259","volume":"32","author":"M Faehling","year":"2015","unstructured":"Faehling M, Wienhausen-Wilke V, Fallscheer S, Trinajstic-Schulz B, Weber J, Leschke M. Long-term stable lung function and second uncomplicated pregnancy on sirolimus in lymphangioleiomyomatosis (LAM). Sarcoidosis Vasc Diffuse Lung Dis. 2015;32(3):259\u201364.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"12","key":"3015_CR19","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1136\/thorax.55.12.1052","volume":"55","author":"SR Johnson","year":"2000","unstructured":"Johnson SR. Clinical experience of lymphangioleiomyomatosis in the UK. Thorax. 2000;55(12):1052\u20137.","journal-title":"Thorax"},{"issue":"5","key":"3015_CR20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/00005792-199909000-00004","volume":"78","author":"T Urban","year":"1999","unstructured":"Urban T, Lazor R, Lacronique J, Murris M, Labrune S, Valeyre D, et al. Pulmonary lymphangioleiomyomatosis. A study of 69 patients Groupe d\u2019Etudes et de Recherche sur les Maladies \u201cOrphelines\u201d Pulmonaires (GERM\"O\"P). Med Baltimore. 1999;78(5):321\u2013237.","journal-title":"Med Baltimore."},{"issue":"10","key":"3015_CR21","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1136\/thoraxjnl-2020-214987","volume":"75","author":"AM Taveira-DaSilva","year":"2020","unstructured":"Taveira-DaSilva AM, Johnson SR, Julien-Williams P, Johnson J, Stylianou M, Moss J. Pregnancy in lymphangioleiomyomatosis: clinical and lung function outcomes in two national cohorts. Thorax. 2020;75(10):904\u20137.","journal-title":"Thorax"},{"issue":"5","key":"3015_CR22","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.rmed.2008.11.007","volume":"103","author":"MM Cohen","year":"2009","unstructured":"Cohen MM, Freyer AM, Johnson SR. Pregnancy experiences among women with lymphangioleiomyomatosis. Respir Med. 2009;103(5):766\u201372.","journal-title":"Respir Med"},{"key":"3015_CR23","unstructured":"BCBSAssociation. Trends in Pregnancy and Childbirth Complications in the U.S.: BCBS Association; 2022 [Available from: https:\/\/www.bcbs.com\/the-health-of-america\/reports\/trends-in-pregnancy-and-childbirth-complications-in-the-us."},{"key":"3015_CR24","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dmcn.15224","volume":"64","author":"AXD Zhang","year":"2022","unstructured":"Zhang AXD, Liang H, Mcewen FS, Tye C, Woodhouse E, Underwood L, et al. Perinatal adversities in tuberous sclerosis complex: determinants and neurodevelopmental outcomes. Dev Med Child Neurol. 2022;64:1237\u201345.","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"3015_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1258\/om.2009.080056","volume":"2","author":"R Mccartney","year":"2009","unstructured":"Mccartney R, Facey N, Chalmers G, Mathers A, Roberts F, Irvine G, et al. Multiple pneumothoraces during second and third trimesters as first presentation of lymphangioleiomyomatosis. Obstet Med. 2009;2(2):84\u20136.","journal-title":"Obstet Med"},{"key":"3015_CR26","unstructured":"Biederman DL. Reproductive-aged adults diagnosed with tuberous sclerosis complex (TSC): understanding of clinical variability, perceived disease burden, and reproductive decision-making: University of South Carolina; 2019."},{"key":"3015_CR27","unstructured":"TSC Clinic Structure and Expertise Requirements for Recognition\/Designation. 1.0 ed. TSC Alliance2020."},{"key":"3015_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.resmer.2023.101010","volume":"83","author":"V Cottin","year":"2023","unstructured":"Cottin V, Blanchard E, Kerjouan M, Lazor R, Reynaud-Gaubert M, Taille C, et al. French recommendations for the diagnosis and management of lymphangioleiomyomatosis. Respirat Med Res. 2023;83: 101010.","journal-title":"Respirat Med Res"},{"issue":"2","key":"3015_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"3015_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.","journal-title":"J Biomed Inform"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-03015-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-03015-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-03015-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T16:13:37Z","timestamp":1704212017000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-03015-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3015"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-03015-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"20 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was certified as exempt from review by Cincinnati Children\u2019s Hospital Medical Center Institutional Review Board (ID: 2022\u20130301).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}